Abstract:Besides its short serum half‐life and independence from kidney function, soluble B‐cell maturation antigen represents a reliable and convenient tool for disease monitoring in patients with nonsecretory or oligosecretory multiple myeloma (MM). Numerous studies have suggested its utility in MM diagnosis, prognostication, and response evaluation, but is it ready for prime time? B‐cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody‐drug conjugates, bispecific antibodies, and chimeric antigen receptor T‐cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma‐secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme‐linked immunosorbent assays, as well as through mass spectrometry‐based proteomics. Besides its short serum half‐life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti‐myeloma therapies. In short, sBCMA might be the "Swiss army knife" of MM laboratory testing, but is it ready for prime time?

Soluble B‐cell maturation antigen in multiple myeloma